Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hidradenitis Suppurativa | 52 | 2024 | 177 | 21.640 |
Why?
|
Psoriasis | 110 | 2023 | 946 | 20.370 |
Why?
|
Dermatologic Agents | 35 | 2022 | 313 | 8.550 |
Why?
|
Dermatology | 52 | 2024 | 918 | 7.630 |
Why?
|
Acne Vulgaris | 20 | 2022 | 349 | 5.120 |
Why?
|
Biological Products | 18 | 2024 | 915 | 3.270 |
Why?
|
Skin Diseases | 23 | 2020 | 1095 | 3.250 |
Why?
|
Severity of Illness Index | 67 | 2024 | 15841 | 2.870 |
Why?
|
Pruritus | 8 | 2021 | 378 | 2.520 |
Why?
|
Career Choice | 13 | 2016 | 757 | 2.340 |
Why?
|
Antibodies, Monoclonal | 27 | 2022 | 9187 | 2.080 |
Why?
|
Quality of Life | 40 | 2022 | 13367 | 1.800 |
Why?
|
Appointments and Schedules | 5 | 2016 | 442 | 1.700 |
Why?
|
Skin Aging | 5 | 2019 | 140 | 1.630 |
Why?
|
Cost of Illness | 8 | 2023 | 1936 | 1.490 |
Why?
|
Sunlight | 4 | 2024 | 337 | 1.390 |
Why?
|
Anti-Inflammatory Agents | 11 | 2024 | 1812 | 1.390 |
Why?
|
Mohs Surgery | 5 | 2011 | 222 | 1.350 |
Why?
|
Pregnancy Complications | 11 | 2024 | 2949 | 1.310 |
Why?
|
Humans | 308 | 2024 | 761208 | 1.290 |
Why?
|
Double-Blind Method | 38 | 2024 | 12341 | 1.240 |
Why?
|
Tumor Necrosis Factor-alpha | 15 | 2024 | 4340 | 1.220 |
Why?
|
Receptors, Tumor Necrosis Factor | 9 | 2014 | 585 | 1.200 |
Why?
|
Biological Therapy | 5 | 2022 | 139 | 1.190 |
Why?
|
Dermatitis, Atopic | 5 | 2022 | 731 | 1.160 |
Why?
|
Cicatrix | 4 | 2020 | 793 | 1.130 |
Why?
|
Clobetasol | 4 | 2008 | 33 | 1.090 |
Why?
|
Clindamycin | 3 | 2012 | 139 | 1.090 |
Why?
|
Training Support | 4 | 2014 | 108 | 1.090 |
Why?
|
Rosacea | 3 | 2014 | 59 | 1.070 |
Why?
|
Female | 181 | 2024 | 392544 | 1.040 |
Why?
|
Adult | 135 | 2024 | 221119 | 1.040 |
Why?
|
Burnout, Professional | 4 | 2024 | 703 | 1.020 |
Why?
|
Interleukin-23 | 10 | 2022 | 201 | 0.970 |
Why?
|
Physician Assistants | 3 | 2015 | 190 | 0.970 |
Why?
|
Skin Neoplasms | 13 | 2016 | 5809 | 0.950 |
Why?
|
Reminder Systems | 4 | 2016 | 386 | 0.940 |
Why?
|
Job Satisfaction | 7 | 2017 | 545 | 0.930 |
Why?
|
Treatment Outcome | 63 | 2024 | 64681 | 0.930 |
Why?
|
Dermatitis | 2 | 2022 | 202 | 0.920 |
Why?
|
Middle Aged | 118 | 2024 | 220853 | 0.920 |
Why?
|
Immunologic Factors | 6 | 2024 | 1589 | 0.900 |
Why?
|
Male | 146 | 2024 | 360693 | 0.900 |
Why?
|
Immunoglobulin G | 10 | 2022 | 4537 | 0.890 |
Why?
|
Nurse Practitioners | 3 | 2015 | 269 | 0.890 |
Why?
|
Skin | 16 | 2023 | 4473 | 0.880 |
Why?
|
Patient Compliance | 7 | 2017 | 2688 | 0.850 |
Why?
|
Pain Measurement | 7 | 2018 | 3549 | 0.840 |
Why?
|
Sunscreening Agents | 4 | 2010 | 139 | 0.820 |
Why?
|
Pregnancy Outcome | 8 | 2024 | 2923 | 0.820 |
Why?
|
Product Surveillance, Postmarketing | 3 | 2024 | 454 | 0.820 |
Why?
|
Calcitriol | 3 | 2010 | 295 | 0.810 |
Why?
|
Economic Recession | 2 | 2016 | 79 | 0.810 |
Why?
|
Arthritis, Psoriatic | 4 | 2009 | 219 | 0.800 |
Why?
|
Sebum | 1 | 2021 | 17 | 0.790 |
Why?
|
Tretinoin | 3 | 2015 | 517 | 0.770 |
Why?
|
Ambulatory Care | 5 | 2015 | 2770 | 0.760 |
Why?
|
Placebos | 6 | 2020 | 1666 | 0.760 |
Why?
|
Registries | 12 | 2021 | 8247 | 0.750 |
Why?
|
Drug Eruptions | 3 | 2016 | 335 | 0.730 |
Why?
|
Benzoyl Peroxide | 2 | 2011 | 22 | 0.730 |
Why?
|
Hyperpigmentation | 2 | 2015 | 116 | 0.730 |
Why?
|
Ethinyl Estradiol | 2 | 2013 | 113 | 0.710 |
Why?
|
Coal Tar | 2 | 2010 | 17 | 0.710 |
Why?
|
Phototherapy | 5 | 2017 | 368 | 0.670 |
Why?
|
Androstenes | 2 | 2013 | 181 | 0.670 |
Why?
|
Career Mobility | 2 | 2012 | 259 | 0.660 |
Why?
|
Comorbidity | 16 | 2021 | 10516 | 0.660 |
Why?
|
Primary Health Care | 5 | 2021 | 4678 | 0.650 |
Why?
|
Administration, Topical | 12 | 2019 | 703 | 0.640 |
Why?
|
Interleukin-12 | 7 | 2020 | 578 | 0.640 |
Why?
|
Contraceptives, Oral | 2 | 2014 | 554 | 0.640 |
Why?
|
Skin Physiological Phenomena | 2 | 2012 | 189 | 0.630 |
Why?
|
Workflow | 2 | 2014 | 850 | 0.630 |
Why?
|
Biological Factors | 1 | 2019 | 158 | 0.620 |
Why?
|
Efficiency | 6 | 2011 | 476 | 0.610 |
Why?
|
Physicians, Women | 6 | 2013 | 510 | 0.600 |
Why?
|
Motivation | 3 | 2018 | 2002 | 0.600 |
Why?
|
Placebo Effect | 3 | 2017 | 518 | 0.600 |
Why?
|
Faculty, Medical | 4 | 2017 | 1205 | 0.600 |
Why?
|
Pyrazines | 1 | 2024 | 1202 | 0.590 |
Why?
|
Ultraviolet Rays | 2 | 2017 | 1078 | 0.590 |
Why?
|
Professional Practice | 5 | 2017 | 313 | 0.590 |
Why?
|
Young Adult | 42 | 2024 | 59221 | 0.580 |
Why?
|
Immunosuppressive Agents | 9 | 2020 | 4190 | 0.580 |
Why?
|
Internship and Residency | 9 | 2017 | 5885 | 0.580 |
Why?
|
Needs Assessment | 4 | 2018 | 1141 | 0.570 |
Why?
|
Insurance Claim Reporting | 1 | 2018 | 165 | 0.570 |
Why?
|
Biopsy | 5 | 2021 | 6781 | 0.560 |
Why?
|
Baths | 2 | 2008 | 53 | 0.560 |
Why?
|
Skin Pigmentation | 3 | 2009 | 277 | 0.560 |
Why?
|
United States | 45 | 2023 | 72339 | 0.560 |
Why?
|
Forecasting | 5 | 2018 | 2928 | 0.550 |
Why?
|
Physicians, Primary Care | 2 | 2021 | 619 | 0.550 |
Why?
|
Therapeutic Human Experimentation | 2 | 2006 | 43 | 0.550 |
Why?
|
Physicians | 8 | 2017 | 4584 | 0.540 |
Why?
|
Skin Care | 2 | 2007 | 56 | 0.540 |
Why?
|
Databases, Factual | 7 | 2018 | 7966 | 0.540 |
Why?
|
Administration, Cutaneous | 9 | 2013 | 713 | 0.530 |
Why?
|
Adolescent | 39 | 2023 | 88298 | 0.530 |
Why?
|
Interleukin-17 | 5 | 2024 | 913 | 0.530 |
Why?
|
Sensory Thresholds | 1 | 2017 | 377 | 0.510 |
Why?
|
Medicine | 1 | 2024 | 942 | 0.510 |
Why?
|
Waiting Lists | 4 | 2014 | 766 | 0.500 |
Why?
|
Television | 1 | 2018 | 407 | 0.500 |
Why?
|
Hospitalists | 1 | 2019 | 294 | 0.500 |
Why?
|
Contraceptives, Oral, Combined | 3 | 2014 | 116 | 0.500 |
Why?
|
Drug Administration Schedule | 15 | 2024 | 4851 | 0.500 |
Why?
|
Pain | 6 | 2020 | 5072 | 0.500 |
Why?
|
Self-Assessment | 2 | 2020 | 399 | 0.490 |
Why?
|
Practice Guidelines as Topic | 7 | 2019 | 7400 | 0.490 |
Why?
|
Smoking | 7 | 2020 | 9055 | 0.490 |
Why?
|
Self Concept | 4 | 2015 | 1046 | 0.490 |
Why?
|
Cardiovascular Diseases | 10 | 2020 | 15520 | 0.490 |
Why?
|
Iontophoresis | 1 | 2015 | 74 | 0.490 |
Why?
|
Salaries and Fringe Benefits | 3 | 2012 | 256 | 0.480 |
Why?
|
Epidermis | 4 | 2022 | 526 | 0.480 |
Why?
|
Prevalence | 16 | 2020 | 15721 | 0.480 |
Why?
|
Spironolactone | 1 | 2018 | 412 | 0.470 |
Why?
|
Health Services Needs and Demand | 3 | 2021 | 1401 | 0.460 |
Why?
|
Leuprolide | 1 | 2016 | 312 | 0.460 |
Why?
|
Fellowships and Scholarships | 5 | 2012 | 1115 | 0.460 |
Why?
|
Social Stigma | 3 | 2015 | 770 | 0.460 |
Why?
|
Antirheumatic Agents | 4 | 2019 | 1369 | 0.450 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2015 | 190 | 0.450 |
Why?
|
Single-Blind Method | 8 | 2015 | 1577 | 0.440 |
Why?
|
Aged | 50 | 2023 | 169288 | 0.440 |
Why?
|
Niacinamide | 2 | 2020 | 413 | 0.440 |
Why?
|
Leadership | 3 | 2015 | 1385 | 0.440 |
Why?
|
Pyrazoles | 1 | 2024 | 2010 | 0.430 |
Why?
|
Practice Management, Medical | 1 | 2015 | 191 | 0.430 |
Why?
|
Randomized Controlled Trials as Topic | 14 | 2018 | 10218 | 0.420 |
Why?
|
Androgen Antagonists | 2 | 2019 | 1408 | 0.420 |
Why?
|
Metabolomics | 2 | 2012 | 1658 | 0.410 |
Why?
|
Hospitals, General | 2 | 2013 | 799 | 0.410 |
Why?
|
Anti-Bacterial Agents | 8 | 2021 | 7407 | 0.410 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2015 | 370 | 0.400 |
Why?
|
Patient Care Planning | 2 | 2016 | 901 | 0.400 |
Why?
|
Inflammation | 10 | 2022 | 10759 | 0.400 |
Why?
|
Herpes Simplex | 1 | 2015 | 465 | 0.390 |
Why?
|
Organometallic Compounds | 1 | 2015 | 647 | 0.390 |
Why?
|
Patient Satisfaction | 7 | 2018 | 3453 | 0.390 |
Why?
|
Women | 1 | 2013 | 224 | 0.380 |
Why?
|
Hematoma | 2 | 2006 | 763 | 0.380 |
Why?
|
Dose-Response Relationship, Drug | 13 | 2017 | 10756 | 0.380 |
Why?
|
Biomedical Research | 3 | 2016 | 3434 | 0.380 |
Why?
|
Pilot Projects | 12 | 2022 | 8642 | 0.370 |
Why?
|
Obesity | 5 | 2020 | 12939 | 0.360 |
Why?
|
Physician-Patient Relations | 5 | 2020 | 3253 | 0.360 |
Why?
|
Role | 1 | 2011 | 176 | 0.360 |
Why?
|
Students | 3 | 2012 | 1737 | 0.360 |
Why?
|
Health Surveys | 4 | 2010 | 4037 | 0.350 |
Why?
|
Hyperlipidemias | 3 | 2011 | 771 | 0.350 |
Why?
|
Data Collection | 10 | 2010 | 3320 | 0.350 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2016 | 4014 | 0.350 |
Why?
|
Salicylic Acid | 1 | 2010 | 62 | 0.350 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2016 | 1146 | 0.350 |
Why?
|
Office Visits | 2 | 2015 | 593 | 0.340 |
Why?
|
Photosensitivity Disorders | 2 | 2012 | 79 | 0.340 |
Why?
|
Dyslipidemias | 3 | 2015 | 870 | 0.340 |
Why?
|
Information Dissemination | 1 | 2018 | 1129 | 0.340 |
Why?
|
Emollients | 2 | 2006 | 42 | 0.340 |
Why?
|
Pemphigus | 1 | 2011 | 107 | 0.340 |
Why?
|
Epidemiologic Studies | 1 | 2013 | 677 | 0.340 |
Why?
|
Population Groups | 1 | 2010 | 207 | 0.330 |
Why?
|
Schools, Medical | 1 | 2016 | 878 | 0.330 |
Why?
|
Age Factors | 12 | 2021 | 18384 | 0.330 |
Why?
|
Melanoma | 5 | 2012 | 5694 | 0.330 |
Why?
|
Geography | 1 | 2011 | 652 | 0.330 |
Why?
|
Glucosamine | 1 | 2009 | 128 | 0.330 |
Why?
|
Privacy | 1 | 2011 | 233 | 0.330 |
Why?
|
Back Pain | 1 | 2013 | 545 | 0.320 |
Why?
|
Joint Diseases | 1 | 2013 | 460 | 0.320 |
Why?
|
Vulnerable Populations | 1 | 2015 | 706 | 0.320 |
Why?
|
Foot Dermatoses | 1 | 2009 | 47 | 0.320 |
Why?
|
Hand Dermatoses | 1 | 2009 | 62 | 0.320 |
Why?
|
Referral and Consultation | 5 | 2021 | 3608 | 0.320 |
Why?
|
Onychomycosis | 1 | 2009 | 50 | 0.320 |
Why?
|
Mental Disorders | 3 | 2015 | 6823 | 0.320 |
Why?
|
Time Factors | 19 | 2021 | 39957 | 0.320 |
Why?
|
Latent Tuberculosis | 1 | 2012 | 224 | 0.320 |
Why?
|
Negative-Pressure Wound Therapy | 3 | 2022 | 156 | 0.310 |
Why?
|
Professional-Patient Relations | 1 | 2014 | 723 | 0.310 |
Why?
|
Ethics, Research | 2 | 2006 | 176 | 0.310 |
Why?
|
Retrospective Studies | 26 | 2024 | 80674 | 0.310 |
Why?
|
Ethics Committees, Research | 2 | 2006 | 196 | 0.310 |
Why?
|
Massachusetts | 8 | 2020 | 8837 | 0.310 |
Why?
|
Metabolic Diseases | 1 | 2015 | 680 | 0.300 |
Why?
|
Neoplasms | 8 | 2018 | 22140 | 0.300 |
Why?
|
Suicidal Ideation | 2 | 2016 | 1447 | 0.300 |
Why?
|
Acetylglucosamine | 1 | 2009 | 189 | 0.300 |
Why?
|
Myocardial Infarction | 4 | 2012 | 11476 | 0.300 |
Why?
|
Clinical Competence | 3 | 2020 | 4788 | 0.300 |
Why?
|
Attitude to Health | 3 | 2012 | 2026 | 0.290 |
Why?
|
Cytokines | 3 | 2020 | 7386 | 0.290 |
Why?
|
Respiratory Tract Diseases | 1 | 2013 | 748 | 0.290 |
Why?
|
Psychometrics | 1 | 2017 | 3061 | 0.290 |
Why?
|
Triage | 1 | 2014 | 985 | 0.290 |
Why?
|
Age Distribution | 5 | 2015 | 2871 | 0.290 |
Why?
|
Carotenoids | 1 | 2010 | 621 | 0.290 |
Why?
|
Absenteeism | 3 | 2018 | 247 | 0.290 |
Why?
|
Lichen Planus | 1 | 2008 | 70 | 0.290 |
Why?
|
Gynecology | 1 | 2013 | 528 | 0.290 |
Why?
|
Adaptation, Psychological | 4 | 2016 | 2632 | 0.290 |
Why?
|
Schools | 1 | 2016 | 1483 | 0.290 |
Why?
|
Stress, Psychological | 4 | 2017 | 4487 | 0.280 |
Why?
|
Osteopathic Medicine | 1 | 2007 | 13 | 0.280 |
Why?
|
Photography | 2 | 2011 | 532 | 0.280 |
Why?
|
Water Loss, Insensible | 1 | 2006 | 12 | 0.280 |
Why?
|
Drugs, Investigational | 1 | 2009 | 212 | 0.280 |
Why?
|
Drug Industry | 2 | 2011 | 788 | 0.280 |
Why?
|
Diabetes Mellitus | 3 | 2023 | 5842 | 0.280 |
Why?
|
Sweating | 1 | 2008 | 155 | 0.280 |
Why?
|
Risk Factors | 23 | 2020 | 74239 | 0.270 |
Why?
|
Telemedicine | 2 | 2021 | 3051 | 0.270 |
Why?
|
Medically Underserved Area | 1 | 2009 | 254 | 0.270 |
Why?
|
Mycosis Fungoides | 2 | 2013 | 170 | 0.270 |
Why?
|
Body Surface Area | 3 | 2020 | 197 | 0.270 |
Why?
|
Stem Cell Transplantation | 1 | 2015 | 1600 | 0.270 |
Why?
|
Pregnancy | 16 | 2024 | 29893 | 0.270 |
Why?
|
Cohort Studies | 11 | 2022 | 41496 | 0.270 |
Why?
|
Health Care Surveys | 3 | 2017 | 2425 | 0.270 |
Why?
|
Specialties, Surgical | 1 | 2011 | 389 | 0.270 |
Why?
|
Obstetrics | 1 | 2013 | 668 | 0.270 |
Why?
|
Nail Diseases | 1 | 2006 | 55 | 0.260 |
Why?
|
Genomics | 2 | 2012 | 5828 | 0.260 |
Why?
|
Suicide | 2 | 2016 | 1602 | 0.260 |
Why?
|
Dimethylpolysiloxanes | 1 | 2006 | 142 | 0.260 |
Why?
|
Antihypertensive Agents | 1 | 2016 | 2019 | 0.260 |
Why?
|
Adrenal Insufficiency | 1 | 2008 | 194 | 0.260 |
Why?
|
Hyperthyroidism | 1 | 2008 | 294 | 0.260 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2010 | 549 | 0.260 |
Why?
|
Camellia sinensis | 1 | 2005 | 8 | 0.260 |
Why?
|
Endpoint Determination | 1 | 2008 | 590 | 0.260 |
Why?
|
Electrocoagulation | 1 | 2006 | 151 | 0.250 |
Why?
|
Patient Participation | 1 | 2015 | 1445 | 0.250 |
Why?
|
Disclosure | 1 | 2011 | 747 | 0.250 |
Why?
|
Treatment Refusal | 2 | 2006 | 430 | 0.250 |
Why?
|
Abscess | 3 | 2024 | 605 | 0.250 |
Why?
|
Drug Delivery Systems | 2 | 2016 | 2223 | 0.250 |
Why?
|
Mass Screening | 3 | 2017 | 5426 | 0.250 |
Why?
|
Academic Medical Centers | 5 | 2021 | 2756 | 0.250 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 8003 | 0.240 |
Why?
|
Cohort Effect | 1 | 2004 | 39 | 0.240 |
Why?
|
Aircraft | 1 | 2006 | 130 | 0.240 |
Why?
|
Pelvic Floor | 1 | 2006 | 138 | 0.240 |
Why?
|
Workload | 2 | 2017 | 845 | 0.240 |
Why?
|
Aged, 80 and over | 14 | 2021 | 58952 | 0.240 |
Why?
|
Gene Expression | 4 | 2021 | 7571 | 0.240 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2016 | 2254 | 0.240 |
Why?
|
Metronidazole | 1 | 2006 | 232 | 0.240 |
Why?
|
Thumb | 1 | 2006 | 232 | 0.240 |
Why?
|
Quality Assurance, Health Care | 1 | 2015 | 2164 | 0.230 |
Why?
|
Cubozoa | 1 | 2004 | 2 | 0.230 |
Why?
|
Seasons | 2 | 2024 | 1518 | 0.230 |
Why?
|
Incidence | 9 | 2017 | 21365 | 0.230 |
Why?
|
Nails | 1 | 2006 | 296 | 0.230 |
Why?
|
Cnidarian Venoms | 1 | 2004 | 19 | 0.230 |
Why?
|
Antivenins | 1 | 2004 | 18 | 0.230 |
Why?
|
Antifungal Agents | 1 | 2009 | 752 | 0.230 |
Why?
|
Research Design | 2 | 2020 | 6180 | 0.230 |
Why?
|
Health Education | 2 | 2010 | 1049 | 0.230 |
Why?
|
Radio Frequency Identification Device | 2 | 2014 | 24 | 0.220 |
Why?
|
Politics | 1 | 2010 | 814 | 0.220 |
Why?
|
Necrobiosis Lipoidica | 1 | 2023 | 14 | 0.220 |
Why?
|
Pyridines | 1 | 2015 | 2872 | 0.220 |
Why?
|
Gels | 3 | 2014 | 420 | 0.220 |
Why?
|
Periodicals as Topic | 4 | 2008 | 1463 | 0.220 |
Why?
|
Intention to Treat Analysis | 2 | 2016 | 413 | 0.220 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2016 | 858 | 0.220 |
Why?
|
Risk Assessment | 14 | 2019 | 24021 | 0.220 |
Why?
|
School Health Services | 1 | 2007 | 384 | 0.210 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2014 | 4021 | 0.210 |
Why?
|
Radiation Protection | 1 | 2007 | 426 | 0.210 |
Why?
|
Hypothyroidism | 1 | 2008 | 668 | 0.210 |
Why?
|
Bites and Stings | 1 | 2004 | 93 | 0.210 |
Why?
|
Follow-Up Studies | 15 | 2019 | 39126 | 0.210 |
Why?
|
Cost-Benefit Analysis | 6 | 2019 | 5493 | 0.210 |
Why?
|
Sex Factors | 8 | 2017 | 10553 | 0.210 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2012 | 2054 | 0.210 |
Why?
|
Dietary Supplements | 3 | 2016 | 3410 | 0.210 |
Why?
|
Radiography | 1 | 2013 | 6974 | 0.200 |
Why?
|
Sclerosing Solutions | 1 | 2022 | 79 | 0.200 |
Why?
|
Medicare | 3 | 2019 | 6773 | 0.200 |
Why?
|
Ginkgo biloba | 1 | 2002 | 26 | 0.200 |
Why?
|
Cross-Over Studies | 4 | 2019 | 2082 | 0.200 |
Why?
|
Propionibacterium acnes | 1 | 2022 | 59 | 0.200 |
Why?
|
Depressive Disorder | 3 | 2017 | 3727 | 0.200 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2002 | 142 | 0.190 |
Why?
|
Quality of Health Care | 2 | 2014 | 4320 | 0.190 |
Why?
|
Social Class | 1 | 2010 | 1993 | 0.190 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 287 | 0.190 |
Why?
|
Phytotherapy | 1 | 2003 | 296 | 0.190 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2002 | 164 | 0.190 |
Why?
|
Adrenal Cortex Hormones | 2 | 2009 | 1878 | 0.190 |
Why?
|
Medicaid | 3 | 2019 | 2813 | 0.190 |
Why?
|
RNA, Ribosomal, 16S | 2 | 2022 | 1032 | 0.180 |
Why?
|
Autoimmune Diseases | 3 | 2015 | 2244 | 0.180 |
Why?
|
Medically Uninsured | 1 | 2006 | 834 | 0.180 |
Why?
|
Drainage | 1 | 2006 | 1157 | 0.180 |
Why?
|
Drug Combinations | 3 | 2012 | 2048 | 0.180 |
Why?
|
Canada | 5 | 2021 | 2125 | 0.180 |
Why?
|
Stroke | 3 | 2012 | 9721 | 0.180 |
Why?
|
Face | 2 | 2021 | 1025 | 0.180 |
Why?
|
Health Care Costs | 4 | 2019 | 3239 | 0.180 |
Why?
|
Swimming | 1 | 2021 | 208 | 0.180 |
Why?
|
Depression | 3 | 2017 | 8132 | 0.180 |
Why?
|
Opioid-Related Disorders | 1 | 2015 | 2164 | 0.180 |
Why?
|
Income | 2 | 2006 | 1869 | 0.180 |
Why?
|
Rejuvenation | 1 | 2021 | 105 | 0.180 |
Why?
|
Cytarabine | 1 | 2002 | 697 | 0.180 |
Why?
|
Administration, Oral | 4 | 2019 | 4015 | 0.180 |
Why?
|
Hematologic Diseases | 1 | 2024 | 496 | 0.170 |
Why?
|
Hydrocortisone | 1 | 2008 | 1818 | 0.170 |
Why?
|
Weight Loss | 1 | 2011 | 2680 | 0.170 |
Why?
|
Psychiatry | 1 | 2012 | 1699 | 0.170 |
Why?
|
Interleukin-23 Subunit p19 | 1 | 2019 | 23 | 0.170 |
Why?
|
Skin Abnormalities | 1 | 2000 | 60 | 0.170 |
Why?
|
Informed Consent | 1 | 2006 | 1008 | 0.170 |
Why?
|
Travel | 1 | 2006 | 796 | 0.170 |
Why?
|
Pyoderma Gangrenosum | 1 | 2021 | 84 | 0.170 |
Why?
|
Patient Acceptance of Health Care | 3 | 2010 | 3200 | 0.170 |
Why?
|
Patient Selection | 2 | 2009 | 4246 | 0.160 |
Why?
|
Recombinant Fusion Proteins | 1 | 2008 | 3726 | 0.160 |
Why?
|
Analgesics, Opioid | 1 | 2015 | 3805 | 0.160 |
Why?
|
Child | 13 | 2020 | 80152 | 0.160 |
Why?
|
Internet | 1 | 2011 | 3096 | 0.160 |
Why?
|
Research Personnel | 2 | 2016 | 588 | 0.160 |
Why?
|
Cross-Sectional Studies | 9 | 2021 | 26071 | 0.160 |
Why?
|
Boston | 3 | 2021 | 9327 | 0.160 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2002 | 646 | 0.160 |
Why?
|
Prospective Studies | 11 | 2022 | 54435 | 0.160 |
Why?
|
Communication | 3 | 2020 | 3872 | 0.160 |
Why?
|
Abdomen | 1 | 2004 | 1128 | 0.160 |
Why?
|
Multivariate Analysis | 4 | 2013 | 12052 | 0.150 |
Why?
|
Nutrition Surveys | 1 | 2006 | 1723 | 0.150 |
Why?
|
Health Status Disparities | 1 | 2010 | 1847 | 0.150 |
Why?
|
Socioeconomic Factors | 4 | 2015 | 7804 | 0.150 |
Why?
|
Health Resources | 3 | 2010 | 934 | 0.150 |
Why?
|
Insurance, Health, Reimbursement | 3 | 2017 | 385 | 0.150 |
Why?
|
Parenting | 1 | 2004 | 701 | 0.150 |
Why?
|
Exanthema | 1 | 2002 | 503 | 0.150 |
Why?
|
Herpes Labialis | 1 | 2017 | 28 | 0.150 |
Why?
|
Pharmaceutical Services | 1 | 2019 | 141 | 0.150 |
Why?
|
Professional Practice Location | 2 | 2009 | 56 | 0.150 |
Why?
|
Drug Approval | 2 | 2019 | 812 | 0.140 |
Why?
|
Genetic Predisposition to Disease | 2 | 2017 | 17897 | 0.140 |
Why?
|
Self Report | 3 | 2015 | 3727 | 0.140 |
Why?
|
Cyclobutanes | 1 | 2017 | 57 | 0.140 |
Why?
|
Multiple Myeloma | 1 | 2015 | 5145 | 0.140 |
Why?
|
Dermatomyositis | 1 | 2000 | 258 | 0.140 |
Why?
|
Facial Dermatoses | 1 | 2017 | 86 | 0.140 |
Why?
|
Evidence-Based Medicine | 3 | 2019 | 3691 | 0.140 |
Why?
|
Chronic Disease | 6 | 2021 | 9319 | 0.140 |
Why?
|
Reference Values | 4 | 2010 | 4921 | 0.140 |
Why?
|
Private Practice | 2 | 2009 | 152 | 0.140 |
Why?
|
Interleukin-10 | 1 | 2002 | 1176 | 0.140 |
Why?
|
Hypertension | 3 | 2014 | 8536 | 0.140 |
Why?
|
Prognosis | 8 | 2019 | 29687 | 0.140 |
Why?
|
Diabetes Complications | 2 | 2015 | 1316 | 0.140 |
Why?
|
Employment | 3 | 2009 | 1114 | 0.140 |
Why?
|
Vinyl Compounds | 1 | 2016 | 22 | 0.130 |
Why?
|
Psychotropic Drugs | 2 | 2012 | 885 | 0.130 |
Why?
|
Mitochondria | 2 | 2020 | 3620 | 0.130 |
Why?
|
Nonprescription Drugs | 2 | 2010 | 118 | 0.130 |
Why?
|
Education, Medical, Graduate | 2 | 2010 | 2374 | 0.130 |
Why?
|
Injections, Subcutaneous | 3 | 2024 | 672 | 0.130 |
Why?
|
Mentors | 2 | 2016 | 663 | 0.130 |
Why?
|
Institutional Practice | 1 | 2015 | 16 | 0.130 |
Why?
|
Administration, Intravaginal | 1 | 2016 | 149 | 0.130 |
Why?
|
Stereotyping | 2 | 2010 | 239 | 0.130 |
Why?
|
Plant Extracts | 3 | 2005 | 496 | 0.130 |
Why?
|
Interviews as Topic | 2 | 2017 | 2697 | 0.130 |
Why?
|
Medical Staff | 1 | 2015 | 40 | 0.130 |
Why?
|
Leiomyomatosis | 1 | 2016 | 69 | 0.130 |
Why?
|
Program Evaluation | 3 | 2013 | 2489 | 0.130 |
Why?
|
Managed Care Programs | 3 | 2021 | 937 | 0.130 |
Why?
|
Coronary Disease | 1 | 2010 | 5921 | 0.120 |
Why?
|
Receptors, Interleukin-17 | 1 | 2015 | 82 | 0.120 |
Why?
|
Anxiety | 1 | 2010 | 4569 | 0.120 |
Why?
|
Lentigo | 1 | 2015 | 37 | 0.120 |
Why?
|
Vitamins | 1 | 2003 | 1634 | 0.120 |
Why?
|
Image Enhancement | 1 | 2006 | 2888 | 0.120 |
Why?
|
Solutions | 1 | 2015 | 410 | 0.120 |
Why?
|
von Hippel-Lindau Disease | 1 | 2016 | 151 | 0.120 |
Why?
|
Premature Birth | 2 | 2021 | 1784 | 0.120 |
Why?
|
Health Status Indicators | 3 | 2007 | 970 | 0.120 |
Why?
|
Cosmetic Techniques | 2 | 2008 | 147 | 0.120 |
Why?
|
Physician Executives | 1 | 2015 | 134 | 0.120 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 934 | 0.120 |
Why?
|
Drug Therapy, Combination | 4 | 2019 | 6304 | 0.120 |
Why?
|
Crohn Disease | 3 | 2017 | 2278 | 0.110 |
Why?
|
Tetracyclines | 1 | 2014 | 64 | 0.110 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2016 | 392 | 0.110 |
Why?
|
Longitudinal Studies | 4 | 2021 | 14610 | 0.110 |
Why?
|
Interleukin-1beta | 1 | 2020 | 1002 | 0.110 |
Why?
|
Sex Distribution | 2 | 2015 | 2277 | 0.110 |
Why?
|
Melanosis | 1 | 2015 | 93 | 0.110 |
Why?
|
Social Isolation | 2 | 2009 | 365 | 0.110 |
Why?
|
Transients and Migrants | 1 | 2016 | 165 | 0.110 |
Why?
|
Tuberculin Test | 2 | 2012 | 205 | 0.110 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2005 | 274 | 0.110 |
Why?
|
Epigenomics | 1 | 2019 | 944 | 0.110 |
Why?
|
Nephrogenic Fibrosing Dermopathy | 1 | 2013 | 42 | 0.110 |
Why?
|
Mechlorethamine | 1 | 2013 | 129 | 0.110 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2813 | 0.100 |
Why?
|
Keratoacanthoma | 1 | 2012 | 33 | 0.100 |
Why?
|
Chromatography | 1 | 2012 | 188 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2017 | 1624 | 0.100 |
Why?
|
Warts | 1 | 2012 | 66 | 0.100 |
Why?
|
Decision Making | 3 | 2017 | 3931 | 0.100 |
Why?
|
Wound Healing | 2 | 2021 | 2800 | 0.100 |
Why?
|
Cost Control | 1 | 2015 | 627 | 0.100 |
Why?
|
Rome | 1 | 2011 | 28 | 0.100 |
Why?
|
Probability | 3 | 2009 | 2478 | 0.100 |
Why?
|
Progestins | 1 | 2014 | 301 | 0.100 |
Why?
|
Statistics as Topic | 2 | 2009 | 2359 | 0.100 |
Why?
|
Data Interpretation, Statistical | 2 | 2016 | 2691 | 0.100 |
Why?
|
Sickness Impact Profile | 1 | 2013 | 299 | 0.100 |
Why?
|
Gestational Age | 1 | 2021 | 3580 | 0.100 |
Why?
|
Hirsutism | 1 | 2011 | 68 | 0.100 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 422 | 0.100 |
Why?
|
Dysplastic Nevus Syndrome | 1 | 2011 | 61 | 0.100 |
Why?
|
Keratosis, Actinic | 1 | 2012 | 72 | 0.100 |
Why?
|
Alopecia | 1 | 2016 | 412 | 0.100 |
Why?
|
Reproducibility of Results | 4 | 2015 | 20119 | 0.100 |
Why?
|
London | 1 | 2011 | 233 | 0.100 |
Why?
|
Sample Size | 1 | 2015 | 843 | 0.090 |
Why?
|
Delayed Diagnosis | 1 | 2015 | 465 | 0.090 |
Why?
|
Colitis, Ulcerative | 2 | 2017 | 1920 | 0.090 |
Why?
|
Epithelium | 1 | 2016 | 1603 | 0.090 |
Why?
|
Los Angeles | 1 | 2011 | 244 | 0.090 |
Why?
|
Telephone | 1 | 2015 | 624 | 0.090 |
Why?
|
Rheumatic Diseases | 1 | 2018 | 654 | 0.090 |
Why?
|
Thyroid Diseases | 1 | 2014 | 386 | 0.090 |
Why?
|
Eclampsia | 1 | 2011 | 56 | 0.090 |
Why?
|
Maternal Exposure | 1 | 2018 | 1067 | 0.090 |
Why?
|
Texas | 1 | 2012 | 403 | 0.090 |
Why?
|
Oximes | 1 | 2012 | 303 | 0.090 |
Why?
|
Genetic Diseases, Inborn | 1 | 2016 | 603 | 0.090 |
Why?
|
Exercise | 1 | 2008 | 5874 | 0.090 |
Why?
|
Analgesia | 1 | 2015 | 461 | 0.090 |
Why?
|
T-Lymphocytes | 4 | 2020 | 10203 | 0.090 |
Why?
|
Personality | 1 | 2014 | 553 | 0.090 |
Why?
|
Hong Kong | 1 | 2010 | 164 | 0.090 |
Why?
|
Vagina | 1 | 2016 | 841 | 0.090 |
Why?
|
Logistic Models | 3 | 2017 | 13249 | 0.090 |
Why?
|
Spectrum Analysis | 1 | 2012 | 449 | 0.090 |
Why?
|
Transplantation, Autologous | 1 | 2015 | 2112 | 0.090 |
Why?
|
Work | 1 | 2011 | 195 | 0.090 |
Why?
|
Fibroblasts | 1 | 2020 | 4137 | 0.090 |
Why?
|
Pyrroles | 1 | 2016 | 1124 | 0.090 |
Why?
|
Pyrimidinones | 1 | 2012 | 385 | 0.090 |
Why?
|
Reinforcement Schedule | 1 | 2009 | 123 | 0.080 |
Why?
|
Models, Statistical | 2 | 2015 | 5081 | 0.080 |
Why?
|
Pharmaceutical Vehicles | 1 | 2009 | 57 | 0.080 |
Why?
|
Patient Dropouts | 1 | 2012 | 411 | 0.080 |
Why?
|
Gadolinium DTPA | 1 | 2013 | 823 | 0.080 |
Why?
|
Drug Prescriptions | 1 | 2019 | 1668 | 0.080 |
Why?
|
Alcoholism | 2 | 2014 | 1973 | 0.080 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 13632 | 0.080 |
Why?
|
Ultraviolet Therapy | 2 | 2011 | 84 | 0.080 |
Why?
|
Telecommunications | 1 | 2009 | 79 | 0.080 |
Why?
|
Remission Induction | 1 | 2015 | 2392 | 0.080 |
Why?
|
Triamcinolone Acetonide | 1 | 2009 | 100 | 0.080 |
Why?
|
Carcinoma, Basal Cell | 1 | 2014 | 557 | 0.080 |
Why?
|
Health Status | 3 | 2015 | 4077 | 0.080 |
Why?
|
Pregnancy, High-Risk | 1 | 2009 | 121 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2013 | 617 | 0.080 |
Why?
|
Health Services Accessibility | 1 | 2006 | 5425 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2008 | 628 | 0.080 |
Why?
|
Abnormalities, Drug-Induced | 2 | 2024 | 339 | 0.080 |
Why?
|
Pituitary-Adrenal Function Tests | 1 | 2008 | 30 | 0.080 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2023 | 3417 | 0.080 |
Why?
|
Proteomics | 2 | 2012 | 3840 | 0.080 |
Why?
|
Specialty Boards | 1 | 2010 | 235 | 0.080 |
Why?
|
Residence Characteristics | 1 | 2018 | 2092 | 0.080 |
Why?
|
Cosyntropin | 1 | 2008 | 34 | 0.080 |
Why?
|
Keratolytic Agents | 1 | 2008 | 34 | 0.080 |
Why?
|
Nasopharyngitis | 1 | 2008 | 10 | 0.080 |
Why?
|
Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2008 | 29 | 0.080 |
Why?
|
Emulsions | 1 | 2008 | 152 | 0.070 |
Why?
|
Microwaves | 1 | 2009 | 184 | 0.070 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1780 | 0.070 |
Why?
|
Immunotherapy | 2 | 2017 | 4642 | 0.070 |
Why?
|
Piperidines | 1 | 2016 | 1656 | 0.070 |
Why?
|
Linear Models | 2 | 2010 | 5869 | 0.070 |
Why?
|
Biological Availability | 1 | 2008 | 389 | 0.070 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2008 | 186 | 0.070 |
Why?
|
Japan | 1 | 2011 | 1378 | 0.070 |
Why?
|
Infant, Newborn | 4 | 2023 | 26199 | 0.070 |
Why?
|
New York City | 1 | 2009 | 730 | 0.070 |
Why?
|
Interpersonal Relations | 1 | 2015 | 1437 | 0.070 |
Why?
|
Genitalia, Female | 1 | 2008 | 146 | 0.070 |
Why?
|
Pyridones | 1 | 2012 | 809 | 0.070 |
Why?
|
Conditioning, Classical | 1 | 2009 | 367 | 0.070 |
Why?
|
Empathy | 1 | 2011 | 474 | 0.070 |
Why?
|
Estradiol | 1 | 2014 | 1937 | 0.070 |
Why?
|
Uterine Neoplasms | 1 | 2016 | 1420 | 0.070 |
Why?
|
Certification | 1 | 2010 | 418 | 0.070 |
Why?
|
Publishing | 2 | 2019 | 832 | 0.070 |
Why?
|
Consent Forms | 1 | 2006 | 55 | 0.070 |
Why?
|
Injections, Intramuscular | 1 | 2008 | 555 | 0.070 |
Why?
|
Interdisciplinary Communication | 1 | 2012 | 931 | 0.070 |
Why?
|
Substance-Related Disorders | 2 | 2014 | 4413 | 0.070 |
Why?
|
Diagnosis, Differential | 3 | 2011 | 12976 | 0.070 |
Why?
|
Conflict of Interest | 1 | 2011 | 554 | 0.070 |
Why?
|
New Jersey | 1 | 2007 | 295 | 0.070 |
Why?
|
Imidazoles | 1 | 2012 | 1172 | 0.070 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2010 | 495 | 0.070 |
Why?
|
Dosage Forms | 1 | 2006 | 56 | 0.070 |
Why?
|
Choice Behavior | 1 | 2012 | 825 | 0.070 |
Why?
|
Abortion, Spontaneous | 1 | 2011 | 533 | 0.070 |
Why?
|
Laser Therapy | 2 | 2021 | 1094 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2014 | 22174 | 0.070 |
Why?
|
Electronic Health Records | 2 | 2014 | 4822 | 0.070 |
Why?
|
Health Services Research | 1 | 2014 | 1807 | 0.070 |
Why?
|
Liver Diseases | 1 | 2015 | 1301 | 0.070 |
Why?
|
Gastrointestinal Diseases | 1 | 2015 | 1201 | 0.070 |
Why?
|
Holidays | 1 | 2006 | 40 | 0.070 |
Why?
|
Age of Onset | 1 | 2013 | 3307 | 0.070 |
Why?
|
Anti-Infective Agents, Local | 1 | 2008 | 247 | 0.070 |
Why?
|
Databases as Topic | 1 | 2008 | 473 | 0.060 |
Why?
|
Detergents | 1 | 2006 | 235 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 2 | 2016 | 3753 | 0.060 |
Why?
|
Disability Evaluation | 1 | 2013 | 1834 | 0.060 |
Why?
|
Thoracic Wall | 1 | 2008 | 202 | 0.060 |
Why?
|
Uterine Prolapse | 1 | 2006 | 68 | 0.060 |
Why?
|
Glycerol | 1 | 2006 | 275 | 0.060 |
Why?
|
Teaching | 2 | 2011 | 1171 | 0.060 |
Why?
|
Proportional Hazards Models | 4 | 2017 | 12474 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2019 | 12747 | 0.060 |
Why?
|
Receptors, Interleukin | 1 | 2006 | 242 | 0.060 |
Why?
|
Pulmonary Fibrosis | 1 | 2009 | 505 | 0.060 |
Why?
|
Longevity | 1 | 2013 | 1063 | 0.060 |
Why?
|
Lymphoma | 1 | 2014 | 1898 | 0.060 |
Why?
|
Mental Health | 1 | 2020 | 3251 | 0.060 |
Why?
|
North America | 2 | 2019 | 1284 | 0.060 |
Why?
|
Emotions | 1 | 2017 | 2742 | 0.060 |
Why?
|
Urinary Bladder Diseases | 1 | 2006 | 167 | 0.060 |
Why?
|
Keratins | 1 | 2006 | 498 | 0.060 |
Why?
|
Partnership Practice | 1 | 2004 | 14 | 0.060 |
Why?
|
Giant Cell Arteritis | 1 | 2009 | 307 | 0.060 |
Why?
|
Hospitalization | 3 | 2020 | 10707 | 0.060 |
Why?
|
Vaginal Smears | 1 | 2008 | 499 | 0.060 |
Why?
|
Physical Examination | 2 | 2008 | 1255 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3803 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2016 | 2092 | 0.060 |
Why?
|
Peer Group | 1 | 2010 | 691 | 0.060 |
Why?
|
DNA Methylation | 1 | 2019 | 4384 | 0.060 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3418 | 0.060 |
Why?
|
Melanins | 1 | 2006 | 289 | 0.060 |
Why?
|
Anti-Obesity Agents | 1 | 2008 | 227 | 0.060 |
Why?
|
Norway | 1 | 2006 | 499 | 0.060 |
Why?
|
Public Sector | 1 | 2006 | 264 | 0.060 |
Why?
|
Cardiology | 1 | 2015 | 1693 | 0.060 |
Why?
|
Indoles | 1 | 2012 | 1830 | 0.060 |
Why?
|
Terminal Care | 1 | 2016 | 1760 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8663 | 0.060 |
Why?
|
Pyrimidines | 1 | 2016 | 3027 | 0.060 |
Why?
|
Culture | 1 | 2008 | 623 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2015 | 5250 | 0.060 |
Why?
|
Area Under Curve | 1 | 2008 | 1636 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11067 | 0.060 |
Why?
|
Patients | 2 | 2023 | 906 | 0.060 |
Why?
|
Child, Preschool | 3 | 2014 | 42224 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3777 | 0.060 |
Why?
|
Triazoles | 1 | 2009 | 902 | 0.060 |
Why?
|
Xanthomatosis | 1 | 2003 | 32 | 0.060 |
Why?
|
Academies and Institutes | 1 | 2006 | 318 | 0.060 |
Why?
|
Attitude of Health Personnel | 2 | 2021 | 3885 | 0.050 |
Why?
|
Nursing Diagnosis | 1 | 2003 | 16 | 0.050 |
Why?
|
Janus Kinase 1 | 1 | 2023 | 107 | 0.050 |
Why?
|
Patient-Centered Care | 1 | 2013 | 1427 | 0.050 |
Why?
|
Medication Adherence | 2 | 2012 | 2175 | 0.050 |
Why?
|
Research | 2 | 2009 | 1976 | 0.050 |
Why?
|
Pirenzepine | 1 | 2003 | 116 | 0.050 |
Why?
|
Private Sector | 1 | 2006 | 394 | 0.050 |
Why?
|
Suppuration | 1 | 2002 | 60 | 0.050 |
Why?
|
PUVA Therapy | 1 | 2003 | 101 | 0.050 |
Why?
|
Glucocorticoids | 2 | 2011 | 2159 | 0.050 |
Why?
|
Photochemotherapy | 1 | 2009 | 826 | 0.050 |
Why?
|
Sulfonamides | 1 | 2012 | 1977 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2009 | 961 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2015 | 4027 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
Insurance, Health | 1 | 2015 | 2493 | 0.050 |
Why?
|
Cosmetics | 1 | 2003 | 102 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
Patient Care Team | 1 | 2013 | 2515 | 0.050 |
Why?
|
Recurrence | 2 | 2017 | 8457 | 0.050 |
Why?
|
Marital Status | 1 | 2004 | 425 | 0.050 |
Why?
|
Parents | 1 | 2016 | 3564 | 0.050 |
Why?
|
Education, Medical, Undergraduate | 1 | 2011 | 1072 | 0.050 |
Why?
|
International Classification of Diseases | 1 | 2008 | 915 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6486 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2008 | 6223 | 0.050 |
Why?
|
Minerals | 1 | 2003 | 281 | 0.050 |
Why?
|
Pre-Eclampsia | 1 | 2011 | 1233 | 0.050 |
Why?
|
Cardiovascular Agents | 1 | 2008 | 842 | 0.050 |
Why?
|
Nurse's Role | 1 | 2003 | 188 | 0.050 |
Why?
|
Insurance Claim Review | 1 | 2006 | 741 | 0.050 |
Why?
|
Israel | 1 | 2004 | 718 | 0.050 |
Why?
|
Fee-for-Service Plans | 1 | 2006 | 698 | 0.050 |
Why?
|
Forearm | 1 | 2004 | 427 | 0.050 |
Why?
|
Costs and Cost Analysis | 1 | 2007 | 1664 | 0.050 |
Why?
|
Wounds and Injuries | 1 | 2014 | 2493 | 0.050 |
Why?
|
Motor Activity | 1 | 2011 | 2712 | 0.050 |
Why?
|
Insurance Coverage | 2 | 2017 | 1935 | 0.050 |
Why?
|
Models, Economic | 1 | 2005 | 714 | 0.050 |
Why?
|
Universities | 1 | 2006 | 995 | 0.050 |
Why?
|
Complement C5a | 1 | 2020 | 100 | 0.040 |
Why?
|
Kidney Transplantation | 1 | 2016 | 4242 | 0.040 |
Why?
|
Anxiety Disorders | 1 | 2012 | 2723 | 0.040 |
Why?
|
Buttocks | 1 | 2000 | 112 | 0.040 |
Why?
|
Health Behavior | 1 | 2011 | 2641 | 0.040 |
Why?
|
Respiratory Tract Infections | 1 | 2008 | 1009 | 0.040 |
Why?
|
Contrast Media | 1 | 2013 | 5311 | 0.040 |
Why?
|
History, 21st Century | 1 | 2006 | 1567 | 0.040 |
Why?
|
Disabled Persons | 1 | 2009 | 1224 | 0.040 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2021 | 190 | 0.040 |
Why?
|
Surgery, Plastic | 1 | 2006 | 640 | 0.040 |
Why?
|
Observer Variation | 1 | 2006 | 2610 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15920 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3808 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2004 | 2217 | 0.040 |
Why?
|
Thigh | 1 | 2000 | 239 | 0.040 |
Why?
|
Atherosclerosis | 1 | 2014 | 3406 | 0.040 |
Why?
|
Students, Medical | 1 | 2011 | 1940 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2019 | 280 | 0.040 |
Why?
|
Equipment Design | 1 | 2006 | 3510 | 0.040 |
Why?
|
Metagenomics | 1 | 2021 | 463 | 0.040 |
Why?
|
Body Image | 1 | 2003 | 639 | 0.040 |
Why?
|
History, 20th Century | 1 | 2006 | 2765 | 0.040 |
Why?
|
Recombination, Genetic | 1 | 2002 | 1518 | 0.040 |
Why?
|
Early Detection of Cancer | 1 | 2012 | 3198 | 0.040 |
Why?
|
Northwestern United States | 1 | 2017 | 20 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2016 | 2928 | 0.040 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 8519 | 0.040 |
Why?
|
Population Surveillance | 1 | 2007 | 2598 | 0.030 |
Why?
|
Skin Transplantation | 1 | 2022 | 1091 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 2854 | 0.030 |
Why?
|
Nail-Patella Syndrome | 1 | 2016 | 12 | 0.030 |
Why?
|
Edema | 1 | 2000 | 764 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2007 | 2726 | 0.030 |
Why?
|
Educational Measurement | 1 | 2003 | 1250 | 0.030 |
Why?
|
Beckwith-Wiedemann Syndrome | 1 | 2016 | 45 | 0.030 |
Why?
|
Prescription Fees | 1 | 2017 | 153 | 0.030 |
Why?
|
Birt-Hogg-Dube Syndrome | 1 | 2016 | 40 | 0.030 |
Why?
|
Delphi Technique | 1 | 2019 | 848 | 0.030 |
Why?
|
Models, Theoretical | 1 | 2007 | 3571 | 0.030 |
Why?
|
Vaccination | 1 | 2007 | 3369 | 0.030 |
Why?
|
Minority Groups | 1 | 2002 | 1201 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 3089 | 0.030 |
Why?
|
Fabry Disease | 1 | 2016 | 87 | 0.030 |
Why?
|
Complementary Therapies | 1 | 2019 | 487 | 0.030 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2016 | 114 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2020 | 858 | 0.030 |
Why?
|
Turner Syndrome | 1 | 2016 | 129 | 0.030 |
Why?
|
Caregivers | 1 | 2007 | 2244 | 0.030 |
Why?
|
Bipolar Disorder | 1 | 2012 | 5092 | 0.030 |
Why?
|
Scalp | 1 | 2017 | 389 | 0.030 |
Why?
|
Denmark | 1 | 2017 | 770 | 0.030 |
Why?
|
Postoperative Care | 1 | 2021 | 1468 | 0.030 |
Why?
|
Hormones | 1 | 2017 | 868 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2003 | 2420 | 0.030 |
Why?
|
Algorithms | 1 | 2014 | 14025 | 0.030 |
Why?
|
Keratinocytes | 1 | 2017 | 790 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1111 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1791 | 0.030 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2016 | 246 | 0.030 |
Why?
|
Ointments | 1 | 2013 | 58 | 0.030 |
Why?
|
Candidiasis | 1 | 2015 | 365 | 0.030 |
Why?
|
Body Mass Index | 1 | 2010 | 12952 | 0.030 |
Why?
|
Truth Disclosure | 1 | 2017 | 432 | 0.030 |
Why?
|
Autoimmunity | 1 | 2020 | 1356 | 0.030 |
Why?
|
New England | 1 | 2015 | 1052 | 0.030 |
Why?
|
Aging | 2 | 2021 | 8702 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2009 | 8998 | 0.030 |
Why?
|
Superovulation | 1 | 1992 | 11 | 0.030 |
Why?
|
Insemination, Artificial, Homologous | 1 | 1992 | 17 | 0.030 |
Why?
|
Bacterial Infections | 1 | 2020 | 1390 | 0.030 |
Why?
|
Animals | 5 | 2009 | 168079 | 0.030 |
Why?
|
Immune System | 1 | 2017 | 792 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2002 | 5871 | 0.020 |
Why?
|
Preoperative Care | 1 | 2021 | 2241 | 0.020 |
Why?
|
Acute Disease | 1 | 2002 | 7226 | 0.020 |
Why?
|
RNA | 1 | 2021 | 2709 | 0.020 |
Why?
|
Infant | 1 | 2013 | 36169 | 0.020 |
Why?
|
Coitus | 1 | 1992 | 134 | 0.020 |
Why?
|
Tattooing | 1 | 2011 | 57 | 0.020 |
Why?
|
Phenotype | 2 | 2020 | 16575 | 0.020 |
Why?
|
Homeostasis | 1 | 2022 | 3320 | 0.020 |
Why?
|
Risk | 2 | 2015 | 9616 | 0.020 |
Why?
|
Life Change Events | 1 | 2016 | 952 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2016 | 1186 | 0.020 |
Why?
|
Drug Costs | 1 | 2019 | 1183 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2006 | 4479 | 0.020 |
Why?
|
Tissue Donors | 1 | 2020 | 2335 | 0.020 |
Why?
|
Neurofibromatosis 1 | 1 | 2016 | 561 | 0.020 |
Why?
|
Bacteria | 1 | 2021 | 2190 | 0.020 |
Why?
|
Lipids | 1 | 2021 | 3331 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1662 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1751 | 0.020 |
Why?
|
Neutropenia | 1 | 2015 | 885 | 0.020 |
Why?
|
Sympathectomy | 1 | 1990 | 72 | 0.020 |
Why?
|
Medication Systems | 1 | 2009 | 31 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 2003 | 3064 | 0.020 |
Why?
|
Methotrexate | 1 | 2016 | 1718 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2006 | 15308 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 3134 | 0.020 |
Why?
|
Dysmenorrhea | 1 | 1990 | 98 | 0.020 |
Why?
|
Nevada | 1 | 2008 | 22 | 0.020 |
Why?
|
Androgens | 1 | 2016 | 1283 | 0.020 |
Why?
|
Tacrolimus | 1 | 2011 | 736 | 0.020 |
Why?
|
Tuberous Sclerosis | 1 | 2016 | 1031 | 0.020 |
Why?
|
Communicable Diseases | 1 | 2016 | 873 | 0.020 |
Why?
|
Focus Groups | 1 | 2013 | 1413 | 0.020 |
Why?
|
Foundations | 1 | 2007 | 95 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4744 | 0.020 |
Why?
|
Long-Term Care | 1 | 2011 | 630 | 0.020 |
Why?
|
Puerto Rico | 1 | 2008 | 378 | 0.020 |
Why?
|
Self Disclosure | 1 | 2008 | 249 | 0.020 |
Why?
|
Hematologic Tests | 1 | 2007 | 239 | 0.020 |
Why?
|
Brazil | 1 | 2010 | 1228 | 0.020 |
Why?
|
Antibodies, Antinuclear | 1 | 2007 | 342 | 0.020 |
Why?
|
Genotype | 1 | 2020 | 12985 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2007 | 525 | 0.020 |
Why?
|
Infertility, Female | 1 | 1992 | 761 | 0.020 |
Why?
|
Safety Management | 1 | 2011 | 761 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2021 | 9416 | 0.020 |
Why?
|
California | 1 | 2009 | 1431 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2507 | 0.020 |
Why?
|
Perception | 1 | 2011 | 1198 | 0.020 |
Why?
|
Neutrophils | 1 | 2017 | 3763 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2020 | 18926 | 0.010 |
Why?
|
Peer Review, Research | 1 | 2008 | 339 | 0.010 |
Why?
|
Bibliometrics | 1 | 2008 | 352 | 0.010 |
Why?
|
Life Style | 1 | 2015 | 3907 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2008 | 12159 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 30002 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9652 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2009 | 1472 | 0.010 |
Why?
|
Hyperplasia | 1 | 2006 | 1150 | 0.010 |
Why?
|
Congresses as Topic | 1 | 2008 | 803 | 0.010 |
Why?
|
Keloid | 1 | 2002 | 55 | 0.010 |
Why?
|
Medical Records | 1 | 2007 | 1409 | 0.010 |
Why?
|
Primary Prevention | 1 | 2009 | 1185 | 0.010 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2015 | 2421 | 0.010 |
Why?
|
Apgar Score | 1 | 1980 | 126 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5662 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 36415 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2009 | 2317 | 0.010 |
Why?
|
Fetal Heart | 1 | 1980 | 281 | 0.010 |
Why?
|
Fetal Death | 1 | 1980 | 435 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2013 | 11119 | 0.010 |
Why?
|
Benzodiazepines | 1 | 2003 | 1134 | 0.010 |
Why?
|
Infant Mortality | 1 | 1980 | 752 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9457 | 0.010 |
Why?
|
Menotropins | 1 | 1992 | 41 | 0.010 |
Why?
|
Disease Progression | 1 | 2009 | 13511 | 0.010 |
Why?
|
Life Tables | 1 | 1992 | 364 | 0.010 |
Why?
|
Baltimore | 1 | 1992 | 231 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2006 | 14392 | 0.010 |
Why?
|
Hospitals, University | 1 | 1992 | 565 | 0.010 |
Why?
|
Heart Rate | 1 | 1980 | 4197 | 0.000 |
Why?
|
Schizophrenia | 1 | 2003 | 6930 | 0.000 |
Why?
|
Endometriosis | 1 | 1990 | 870 | 0.000 |
Why?
|
Nurseries, Hospital | 1 | 1980 | 17 | 0.000 |
Why?
|
Mice | 1 | 2006 | 81326 | 0.000 |
Why?
|
Fetal Diseases | 1 | 1980 | 912 | 0.000 |
Why?
|
Infant, Newborn, Diseases | 1 | 1980 | 589 | 0.000 |
Why?
|
Diagnostic Errors | 1 | 1980 | 1265 | 0.000 |
Why?
|
Length of Stay | 1 | 1980 | 6417 | 0.000 |
Why?
|